Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development. 

Biotechnology

Health Care

Therapeutics

Tallac Therapeutics

Hong I. Wan

Kimberli Brill

Peter Dudek

Pavel Strop

Ons H.

Mark Karbarz

Janet Sim 沈彬

Em Abellana

Curtis Hecht

Bora Han

Science and Research

Leadership Team

Teams at Tallac Therapeutics

Science and Research

Leadership Team